Table 7

Study 205: Mean (X) CGI-I (Values less than four represent improvement)

LAST OBSERVATION CARRIED FORWARD ANALYSIS

Treatment Week:

Baseline

Wk 1

Wk 2

Wk 3

Wk 4

Wk 5

Wk 6

Wk 7

Wk 8

Treatment Groups

N

X

N

X

N

X

N

X

N

X

N

X

N

X

N

X

N

X

BUP SR 100 (VL)

112

4.0

106

3.5

112

3.3

112

3.0

112

2.9

112

2.7

112

2.6

112

2.5

112

2.5

BUP SR 200 (L)

114

4.0

106

3.5

114

3.4

114

3.1

114

2.8

114

2.7

114

2.6

114

2.5

114

2.5

BUP SR 300 (M)

110

4.0

105

3.5

11

3.3

110

3.1

110

2.9

110

2.9

110

2.8

11

2.7

110

2.7

BUP SR 400 (II)

111

4.0

107

3.7

111

3.3

111

3.1

111

2.9

111

2.9

111

.28

111

2.7

111

2.7

Placebo (P)

116

4.0

109

3.6

116

3.3

116

3.2

116

3.1

116

3.0

116

2.9

116

2.9

116

2.8

VL. vs P

2-sided

p-values

for

pairwise

compar-

isons

*

0.2

0.6

0.08

0.2

0.09

0.06

0.03

0.04

L vs. P

0.09

0.9

0.3

0.08

0.09

0.04

0.02

0.07

M vs. P

0.1

0.7

0.4

0.4

0.5

0.4

0.2

0.6

II vs. P

0.7

0.9

0.3

0.3

0.7

0.5

0.3

0.6

OBSERVED CASES ANALYSIS

Treatment Week:

Baseline

Wk 1

Wk 2

Wk 3

Wk 4

Wk 5

Wk 6

Wk 7

Wk 8

Treatment Groups

N

X

N

∆

n=N

X

N

X

N

X

N

X

N

X

N

X

N

X

BUP SR 100 (VL)

112

4.0

106

3.5

103

3.2

102

2.9

89

2.8

85

2.6

86

2.4

82

2.3

76

2.2

BUP SR 200 (L)

114

4.0

106

3.5

100

3.3

95

3.0

90

2.7

85

2.6

83

2.4

80

2.2

74

2.2

BUP SR 300 (M)

110

4.0

105

3.5

98

3.2

81

2.8

80

2.6

77

2.5

71

2.3

69

2.2

66

2.2

BUP SR 400 (II)

111

4.0

107

3.7

94

3.2

88

2.9

83

2.7

77

2.7

75

2.5

72

2.3

70

2.3

Placebo (P)

116

4.0

109

3.6

107

3.3

102

3.1

90

2.9

87

2.7

83

2.6

83

2.6

75

2.5

VL. vs P

2-sided

p-values

for

pairwise

compar-

isons

*

0.2

0.4

0.08

0.4

0.2

0.1

0.03

0.1

L vs. P

0.09

0.7

0.2

0.2

0.2

0.09

0.01

0.2

M vs. P

0.1

0.2

0.02

0.06

0.1

0.03

0.01

0.1

II vs. P

0.7

0.2

0.09

0.1

0.5

0.3

0.02

0.3